<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691052</url>
  </required_header>
  <id_info>
    <org_study_id>QoliXane</org_study_id>
    <nct_id>NCT02691052</nct_id>
  </id_info>
  <brief_title>Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program</brief_title>
  <acronym>QoliXane</acronym>
  <official_title>Non-interventional Study on Quality of Life, Efficacy and Tolerability of Nab-paclitaxel/Gemcitabine Firstline Therapy in Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trium Analysis Online GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>mca Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current studies resulted in a superiority of a combination of nab-paclitaxel and gemcitabine
      vs. gemcitabine mono therapy, but no data are available yet on the quality of life (QoL)
      under this combination therapy. In the framework of a German multicenter prospective,
      observational study ('QoliXane'), detailed QoL-data are now collected. QoL development under
      treatment will be analyzed and data will be compared to existing data of the gemcitabine mono
      therapy.

      QoL and course of therapy are collected using the EORTC C30 questionnaires once a month over
      a 6-month period. Additionally patients are requested to answer a supplementary questionnaire
      addressing e.g. fears related to QoL deterioration and side effects of chemotherapy. Primary
      endpoint is the proportion of patients with maintained Global Health Status/QoL at 3 months
      (10 points threshold). 600 patients shall be enrolled at about 90 study sites in Germany.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global Health Status/Quality of Life Score at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of patients without deterioration of their global health status/quality of life score according to EORTC QLQ-C30 after 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Health Status/Quality of Life Score at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of patients with an improvement of their global health status/quality of life score according to EORTC QLQ-C30 after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limited Baseline Condition</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Rate of patients with a limited baseline general condition (ECOG 2 or 3) and stable or improved Global Health Status/Quality of Life Score after 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy effects on Global Health Status/Quality of Life Score</measure>
    <time_frame>3 months</time_frame>
    <description>Effect of therapy on Global Health Status/Quality of Life Score and other symptoms and scales assessed by EORTC QLQ-C30: rate of patients with improved, stable or deteriorated score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic validity of Global Health Status/Quality of Life Score as assessed by tumor response and EORTC QLQ-C30</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time until definitive deterioration of Global Health Status/Quality of Life Score and other functional and symptom scales of EORTC QLQ-C30</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of Neuropathy on Quality of Life compared to other treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Global Health/Quality of Life scores as assessed by EORTC QLQ-C30 to historical Global Health/Quality of Life score data of gemcitabine mono-therapy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response (RECIST)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival as assessed by tumor response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival as assessed by survival data one year after patient enrollment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in high ECOG and high bilirubin patients</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in special subgroups like high ECOG or high bilirubin patients</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations of tumor response and survival with genetic alterations</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Pts receiving nab-paclitaxel/gemcitabine</arm_group_label>
    <description>Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life questionnaire</intervention_name>
    <description>EORTC QLQ-C30 questionnaire</description>
    <arm_group_label>Pts receiving nab-paclitaxel/gemcitabine</arm_group_label>
    <other_name>EORTC QLQ-C30</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor containing tissues are collected for a translational program focusing on defining
      prognostic and predictive factors.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic pancreatic cancer subject to firstline therapy with nab-paclitaxel
        and gemcitabine
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  metastatic pancreatic carcinoma

          -  no previous therapy in the metastatic stage

          -  planned firstline therapy with nab-paclitaxel and gemcitabine

        Exclusion Criteria:

          -  previous therapy in the metastatic stage

          -  patient unable to understand the study and to give informed consent

          -  patient unable to answer quality of life questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Clinical Cancer Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerrit zur Hausen, Dr.</last_name>
    <phone>+49697601</phone>
    <phone_ext>4562</phone_ext>
    <email>zurhausen.gerrit@khnw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Nordwest gGmbH - Institute of Clinical Cancer Research</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrit zur Hausen, Dr.</last_name>
      <phone>+49697601</phone>
      <phone_ext>4562</phone_ext>
      <email>zurhausen.gerrit@khnw.de</email>
    </contact>
    <investigator>
      <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

